CeriBell, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
CeriBell, Inc. (CBLL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $5.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-10
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $2.10M, a 76.40% decline year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $3.50M, a 483.33% increase year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $4.80M, a 433.33% increase year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $3.10M, a 29.17% increase year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $17.40M, a 335.00% increase from fiscal 2024.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $4.00M, a 900.00% increase from fiscal 2023.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $400.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $5.60M 10-Q · filed 2026-08-10 | $10.40M derived: sum of 3 quarters · filed 2026-08-10 | $13.50M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $3.50M 10-Q · filed 2026-05-11 | $8.30M derived: sum of 2 quarters · filed 2026-05-11 | $11.40M derived: sum of 3 quarters · filed 2026-05-11 | $20.30M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.90M derived: sum of 2 quarters · filed 2026-02-24 | $16.80M derived: sum of 3 quarters · filed 2026-08-10 | $17.40M 10-K · filed 2026-02-24 | |
| 2025-09-30 | $3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $12.00M derived: sum of 2 quarters · filed 2026-08-10 | $12.60M 10-Q · filed 2025-11-04 | $13.50M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $9.50M 10-Q · filed 2026-08-10 | $10.40M derived: sum of 3 quarters · filed 2026-08-10 | $12.80M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-11 | $1.50M derived: sum of 2 quarters · filed 2026-05-11 | $3.90M derived: sum of 3 quarters · filed 2026-05-11 | $4.50M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.30M derived: sum of 2 quarters · filed 2026-02-24 | $3.90M derived: sum of 3 quarters · filed 2026-02-24 | $4.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.00M derived: sum of 2 quarters · filed 2025-11-04 | $3.10M 10-Q · filed 2025-11-04 | $33.36M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $700.00K 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | $400.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |